Literatur zum Artikel: Schrör, Huber

K. Schrör; K. Huber

doi:10.1055/s-0037-1617006

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 2007; 27(05): 351-352
DOI: 10.1055/s-0037-1617006

Original Article

Schattauer GmbH

Literatur zum Artikel: Schrör, Huber

Authors

K. Schrör

¹Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität
K. Huber

²3. Medizinischen Abteilung mit Kardiologie und Internistischer Notaufnahme, Wilhelminenspital, Wien

Abstract

Volltext

Referenzen

Literatur
1 Asai F, Jakubowski JA, Hirota T. et al. A comparison of prasugrel (CS-747, LY640315) with clopidogrel on platelet function in healthy male volunteers. J Am Coll Cardiol 2005; 45 Suppl I 87A 868-868.
2 Asai F, Jakubowski JA, Naganuma H. et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y₁₂ inhibitor: a single ascending dose study in healthy humans. Platelets 2006; 17: 209-217.
3 Barragan P, Bouvier J-L, Roquebert P-O. et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Cathet Cardiovasc Intervent 2003; 59: 295-302.
4 Bassand JP, Hamm CW, Ardissino D. et al. ESCGuidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007; 28: 1598-160.
5 Belton O, Byrne D, Kearney D. et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
6 Bliden KP, Chiara J, Tantry US. et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol 2007; 49: 657-666.
7 Brandt JT, Payne CD, Weerakkody G. et al. Superior responder rate for inhiition of platelet aggregation with a 60 mg loading dose of prasugrel (CS-747, LY640315) compared with a 300 mg loading dose of clopidogrel. J Am Coll Cardiol 2005; 45 Suppl I 87A.
8 CAPRIE Steering Committee.. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
9 Cattaneo M, Lecchi A. Inhibition of the platelet P2Y₁₂ receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 2006; 5: 577-582.
10 Farid NA, Payne CD, Small DS. et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-741.
11 Farid NA, Smith RL, Gillespie TA. et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Disp 2007; 35: 1096-1104.
12 Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006; 46: 277-300.
13 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 20: 1420-1425.
14 Grossmann R, Sokolova O, Schnurr A. et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-1206.
15 Gurbel P, Tantry US. Drug Insight: Clopidogrel nonresponsiveness. Nature Clin Practice Cardiovasc Med 2006; 3: 387-395.
16 Gurbel PA, Bliden KP, Hayes KM. et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-1396.
17 Hasegawa M, Sugidachi A, Ogawa T. et al. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y₁₂ receptor inhibitor. Thromb Haemost 2005; 94: 593-598.
18 Hochholzer W, Trenk D, Frundi D. et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 1560-1564.
19 Jakubowski JA, Matsushima N, Asai F. et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y₁₂ inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2006; 63: 421-430.
20 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
21 Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Pharm Res 2006; 23: 2691-2708.
22 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
23 Matsushima N, Jakubowski JA, Asai F. et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y₁₂ inhibitor: A multiple dose study in healthy humans. Platelets 2006; 17: 218-226.
24 Müller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
25 Müller I, Seyfarth M, Rüdiger S. et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
26 Niitsu Y, Jakubowski JA, Sugidachi A. et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y₁₂ receptor antagonist activity. Semin Thromb Hemost 2005; 31: 184-194.
27 Paul BZS, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A2-induced platelet aggregation. J Biol Chem 1999; 41: 29108-29114.
28 Rehmel JLF, Eckstein JA, Farid NA. et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochrome P450. Drug Metab Dispos 2006; 34: 600-607.
29 Schrör K. Ticlopidine and Clopidogrel. In: Ferguson JJ, Chronos NAF, Harrington RA. (eds). Antiplatelet Therapy in Clinical Practice. London: Martin Dunitz Ltd; 2000: 93-111.
30 Schrör K, Weber A-A, Hohlfeld T. Clopidogrel ,,resistance“ and statin cotreatment – significant for cardiocoronary prevention in real life?. Thromb Haemost 2005; 94: 235-237.
31 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
32 Siller-Matula J, Schrör K, Wojta J. et al. Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
33 Snoep JD, Hovens MM, Eikenboom JC. et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231.
34 Sugidachi A, Asai F, Ogawa T. et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonistic properties. Br J Pharmacol 2000; 129: 1439-1446.
35 Sugidachi A, Asai F, Yoneda K. et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747. Br J Pharmacol 2001; 132: 47-54.
36 Sugidachi A, Ogawa T, Kurihara A. et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrels active metabolite. J Thromb Haemost 2007; 5: 1545-1551.
37 Szczeklik A, Krzanowski M, Góra P. et al. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992; 80: 2006-2011.
38 Tantry US, Bliden KP, Gurbel P. Prasugrel. Expert Opin Invest Drugs 2006; 15: 1627-1633.
39 Taubert D, Kastrati A, Harlfinger S. et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-316.
40 Weber A-A, Hohlfeld T, Schrör K. CAMP is an important messenger for ADP-induced platelet aggregation. Platelets 1999; 10: 238-241.
41 Wickremshine ER, Tian Y, Ruterbories KJ. et al. Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatographytandem mass spectrometry method. Drug Metab Dispos 2007; 35: 917-921.
42 Wihlborg A-K, Wang L, Braun OO. et al. ADP receptor P2Y₁₂ is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 1810-1815.
43 Wiviott S, Antman EM, Winters KJ. et al. JUMBOTIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y₁₂ antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medications to Block platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-3373.
44 Wiviott SD, Antman EM, Gibson CM. et al. for the TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006; 152: 627-635.